A 78 year old women…recurring SCC of the face…tumors were characterized: PDL1 (clone E1L3N) 2% and 10%, respectively; scant peritumoral or intratumoral lymphocytes; tumor mutation burden high...Panitumumab was integrated between cycles 2 and 3, resulting in a dramatic abrupt response: the masses became centrally necrotic, flaking, pouring off her face with prompt resolution in edema and complete response (CR) within 2 months - now lasting over 18 months - a period during which pembrolizumab and panitumumab were continued for 27 and 26 cycles respectively)...